Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · THEMISMED

THEMIS MEDIC

HealthcarePharmaceuticals & Biotechnology₹885 cr market cap
₹97.24 ▲ +0.77% today As of 19 Nov 2026
52-week low ₹66.0752-week high ₹133.07

-27.5% from the 52-week high · +46.1% above the low

Themis Medicare Ltd. is a holding company, which engages in the manufacture of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 1,145 full-time employees. The company went IPO on 2007-04-02. The firm operates through one segment: Pharmaceuticals. The firm manufactures therapeutic pharma products, differential healthcare products, and APIs based in India. Its analgesic and anti-inflammatory products include Aquadol Tpm Gel, Etojet 90 10'S, Etojet 120 10'S, Etojet Mr Tablets 10'S, Etojet XP Gel, Themidol-P Tab 10's, Dhoom, Aquadol inj, Dyloaqua inj, Joydol -P, Joydol -SP, Joydol -TH, and Nimujet Gel. Its Analgesics products include Anemol, Tazowin, Themidol, Themidol. Its Anesthesia products include Bupicaine 0.25%, Ketmin 2 Vial, Ketmin 5, Ropicaine 2, Themicaine 2%, and more. Its subsidiaries include Artemis Biotech Limited, Themis Lifestyle Private Limited, and Carpo Medical Limited (UK).

The short version. THEMIS MEDIC reported revenue of ₹90 crore for Sep 2026, up 15.4% from a year earlier. Net profit was ₹7 crore. Return on equity was 0.3% in Mar 2026. Promoter holding was 67.1% in Sep 2026, down 0.05 points over 8 quarters.

1 · The price

How has the stock traded?

THEMIS MEDIC trades 27.5% below its 52-week high and 46.1% above its 52-week low.

Change over period: —

1M-4.0%
3M-7.4%
6M-1.0%
1Y-15.5%

2 · The business

Is it growing?

Sales, year on year+15.4%

Sep 2026 revenue of ₹90 cr.

Net margin7.9%

12.5 pts higher than a year earlier.

3-year growth-72.8% profit

Revenue compounded at -1.3% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue9087779078987294
Net profit725910-4-14-101
Net margin %7.928.311.611.2-4.6-14.6-13.50.6
EPS (₹)0.772.670.961.1-0.39-1.55-1.050.06

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue342406382354395231202184
Net profit1304457733625-11
Net margin %0.37.411.416.118.515.512.3-5.8
EPS (₹)0.123.244.736.187.923.892.7-1.17

3 · The quality

How well does it turn capital into profit?

Return on equity was 0.3% in Mar 2026; debt to equity is 0.25.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %0.37.411.516.8
Return on capital %-0.310.110.718.3
EBITDA margin %2.513.114.621.6
Net margin %0.37.311.315.6

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR-1.3%8.5%
Profit CAGR-72.8%-49.8%
Debt to equity0.25
Interest cover-0.1x
Current ratio1.84
P/E ratio22.3

4 · The owners

Who holds it, and are they adding?

Promoter holding67.1%

Down 0.05 pts over 8 quarters.

Foreign institutions0.01%

Down 0.09 pts over 8 quarters.

Domestic institutions0.01%

Unchanged over 8 quarters.

Mutual fund schemes2

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter67.1567.1567.1567.1567.167.167.167.1-0.05
FII0.10.140.10.060.050.110.010.01-0.09
DII0.010.010.010.010.010.010.010.010.0
Public32.7432.732.7432.7832.8332.7832.8732.87+0.13

Mutual fund holdings · Oct 2026

2 schemes hold this stock

2 the month before.

  • Motilal Oswal BSE Healthcare ETF0.02% of NAV
  • Bandhan BSE Healthcare Index Fund0.02% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for THEMIS MEDIC are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about THEMIS MEDIC

What is the THEMIS MEDIC share price?

THEMIS MEDIC (THEMISMED) last closed at ₹97.24, up 0.77% on the day. Its 52-week range is ₹66.07 to ₹133.07.

What is the market cap of THEMIS MEDIC?

THEMIS MEDIC has a market capitalisation of about ₹885 crore. Its price-to-earnings ratio is 22.3.

How are THEMIS MEDIC's latest results?

THEMIS MEDIC reported revenue of ₹90 crore for Sep 2026, up 15.4% from a year earlier. Net profit was ₹7 crore. Return on equity was 0.3% in Mar 2026. Promoter holding was 67.1% in Sep 2026, down 0.05 points over 8 quarters.

Who owns THEMIS MEDIC?

As of Sep 2026, shareholding was: Promoter 67.1%, FII 0.01%, DII 0.01%, Public 32.87%.

How many mutual funds hold THEMIS MEDIC?

2 mutual fund schemes held THEMIS MEDIC in October 2026. That compares with 2 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 04 Sep 2025 · Final Dividend - Rs. 0.5
  • 12 Jul 2024 · Final Dividend - Rs. 0.5
  • 10 Oct 2023 · Stock Split From Rs.10/- to Rs.1/-
  • 01 Sep 2023 · Final Dividend - Rs. 5
  • 08 Sep 2022 · Final Dividend - Rs. 5
  • 08 Sep 2021 · Final Dividend - Rs. 4.3

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.